

EXHIBIT 26

CONFIDENTIAL

Page 1

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF LOUISIANA

KATHLEEN MOLLER

Plaintiff

CIVIL ACTION

V.

NO. 24-0228-WBV-DPC

MARTIAN SALES, INC., ET AL.

Defendants

CONFIDENTIAL

REMOTE VIDEO-RECORDED EXPERT DEPOSITION OF
MARILYN A. HUESTIS, PHD

Tuesday, January 20, 2026
9:32 AM Eastern Standard Time

Job No. MDLG7824902

Reported by: Denise Dobner Vickery, CRR, RMR

CONFIDENTIAL

Page 2

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Tuesday, January 20, 2026
9:32 AM Eastern Standard Time

Remote Video-Recorded Expert
Deposition of MARILYN A. HUESTIS, PHD, held in
the location of the witness in Washington, DC.

Pursuant to notice, before Denise
Dobner Vickery, Certified Realtime Reporter,
Registered Merit Reporter, and Notary Public in
and for the District of Columbia.

[illegible]

CONFIDENTIAL

Page 125

1 Q. Okay. Now, what is the recommended
2 daily dose for the OPMS kratom at issue in this
3 case?

4 A. I --

5 MS. CONGER: Object to form.

6 THE WITNESS: I don't think
7 they say that.

8 BY MR. COWGILL:

9 Q. That's a little bit of a problem
10 then, isn't it? Because we don't know, you know,
11 how much you're supposed to take.

12 MS. CONGER: Object to form.

13 THE WITNESS: Yeah. They
14 recommend talking to your physician.
15 Because of the potential for interactions
16 and things, that you discuss with the
17 physician how much is appropriate for you
18 to take.

19 BY MR. COWGILL:

20 Q. And you expect physicians to know
21 the answer to that question?

22 A. I don't know. I don't know.

23 Q. Have you ever input kratom into a
24 drug-drug interaction checker used by physicians?

CONFIDENTIAL

Page 186

1 contributed to it.

2 BY MR. COWGILL:

3 Q. So kratom was a contributing factor
4 in this death?

5 MS. CONGER: Object to form.
6 Calls for a legal conclusion and
7 mischaracterizes testimony.

8 THE WITNESS: Along with all
9 the other substances, and it's impossible
10 when you have the different drugs to know
11 the contribution of each one.

12 BY MR. COWGILL:

13 Q. Yeah. So like Papsun says, you
14 know, we have to consider kratom within the whole
15 picture including all the substances and that it
16 may, in fact, be contributory?

17 MS. CONGER: Object to form.

18 THE WITNESS: Along with all
19 the other substances.

20 BY MR. COWGILL:

21 Q. All right. And you see here Papsun
22 also states:

23 "The question is really not if
24 kratom can result in toxicity, but rather at what

CONFIDENTIAL

Page 312

1 mitragynine."

2 Did I read all that correctly?

3 A. Yes.

4 Q. Do you have any disagreements with
5 those statements?

6 MS. CONGER: Object to form.

7 THE WITNESS: No. I didn't
8 write this, but I reviewed it.

9 BY MR. COWGILL:

10 Q. And so what is meant by kratom is
11 misused to increase energy, sociability, produce
12 feelings of happiness, well-being, relaxation, and
13 euphoria?

14 A. So I didn't write it, but I think
15 that the author is saying that some people misuse
16 kratom and take more than is typical. And we know
17 that to be true both in Southeast Asia and here
18 where people may take exceedingly large doses and
19 become dependent on the drug.

20 Q. How is someone supposed to know how
21 much OPMS kratom to take?

22 MS. CONGER: Object to form.

23 THE WITNESS: That I -- I
24 don't know because it says talk to your

CONFIDENTIAL

Page 313

1 physician about it.

2 BY MR. COWGILL:

3 Q. So if someone doesn't know how much
4 to take, how do they know that they're misusing
5 it?

6 A. Well, we --

7 MS. CONGER: Object to form.

8 THE WITNESS: We know that
9 most people take approximately 3 grams of
10 kratom or less a day for the purposes
11 that we've discussed. We know if people
12 take more of the substance and more
13 frequently than that, that some people
14 can become dependent on kratom.

15 BY MR. COWGILL:

16 Q. Do you agree that your clients who
17 sell and market OPMS kratom, manufacture it, do
18 you agree that they should not sell OPMS kratom
19 for the purposes described under the Non-Clinical
20 heading here?

21 MS. CONGER: Object to form
22 and outside the scope of opinion.

23 THE WITNESS: I don't really
24 understand your question. I'm sorry.